Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NNMT | P40261 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539297 | 1.00 | TDP1 (0.53) | TDP1POLBLMNAALDH1A1KDM4E | |
| SCHEMBL1901245 | 0.83 | ALDH1A1 (0.47) | TDP1POLBALDH1A1KDM4ENNMT | |
| SCHEMBL3658112 | 0.81 | POLB (0.44) | TDP1POLBLMNAALDH1A1KDM4E | |
| SCHEMBL17141437 | 0.79 | POLB (0.43) | TDP1POLBLMNAALDH1A1KDM4E | |
| SCHEMBL3650280 | 0.79 | TDP1 (0.47) | TDP1POLBLMNAALDH1A1KDM4E | |
| SCHEMBL3574275 | 0.77 | TDP1 (0.41) | TDP1POLBLMNAALDH1A1KDM4E | |
| SCHEMBL19330148 | 0.76 | TDP1 (0.61) | TDP1POLBLMNAALDH1A1KDM4E | |
| SCHEMBL29774203 | 0.74 | NNMT (0.56) | TDP1POLBLMNAALDH1A1KDM4E | |
| SCHEMBL19330176 | 0.74 | TDP1 (0.59) | TDP1POLBLMNAALDH1A1KDM4E | |
| SCHEMBL1291135 | 0.74 | POLB (0.59) | TDP1POLBLMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| US-8598175-B2 | Heteroarylamide pyrimidone derivatives | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | claimed |
| CN-101563328-B | substituted heteroaryl Pyridopyrimidinone derivatives | SANOFI AVENTIS | 2012-03-14 | — | — | CN | claimed |
| CN-101679306-B | Heteroaryl amide substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | SANOFI-AVENTIS (FR) | 2011-12-28 | — | — | CN | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | claimed |
| CN-101679306-A | Heteroaryl amide substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | SANOFI AVENTIS | 2010-03-24 | — | — | CN | claimed |
| CN-101563328-A | Substituted heteroaryl pyridopyrimidinone derivatives | SANOFI AVENTIS (FR) | 2009-10-21 | — | — | CN | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008155666-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | TDP1 764/4885POLB 1069/4885LMNA 1458/4885 |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, DPYD, HPRT1 | TDP1 1512/4885POLB 1484/4885LMNA 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.